Ide-cel shows promise in triple-class exposed RRMM

Idecabtagene vicleucel (ide-cel) improves treatment response and survival in triple-class exposed patients with relapsed and refractory multiple myeloma (RRMM), as compared to current therapies, a recent study has found.

Researchers conducted a retrospective analysis using data of 1,949 real-world RRMM patients who had been triple-class exposed to an immunomodulatory agent, a proteasome inhibitor (PI), and an anti-CD38 antibody. The primary endpoint was overall response rate (ORR); other outcomes included overall survival (OS) and progression-free survival (PFS).

ORR was 76.4 percent in the ide-cel-treated patients, which was significantly higher than the 32.2 percent rate in nontreated comparators. The resulting risk estimate was statistically significant in favour of ide-cel (risk ratio [RR], 2.4, 95 percent confidence interval [CI], 1.7–3.3; p<0.0001). Similarly, the rate of very good partial response or better was significantly greater in patients who had received ide-cel (RR, 4.2, 95 percent CI, 2.5–7.2; p<0.0001).

Moreover, ide-cel treatment led to a significantly longer PFS (11.6 vs 3.5 months; hazard ratio [HR], 0.54, 95 percent CI, 0.38–0.76; p=0.0004), as well as better OS (20.2 vs 14.7 months; HR, 0.45, 95 percent CI, 0.28–0.71; p=0.0006).

“[O]utcomes are suboptimal with current treatment options in real-world RRMM patients who have received three or more prior therapies, including an immunomodulatory agent, a PI, and an anti-CD38 antibody,” the researchers said.

“This study demonstrated a clear benefit with ide-cel treatment over currently available therapies, with significant increases in efficacy. Thus, ide-cel offers a promising new treatment option in triple-class exposed RRMM,” they added.